Geneva, Switzerland, October 2018. GBC-HpVac SA has successfully concluded a seed financing round, which enables it to proceed with the lead validation phase of its molecule GBC-R1.
The production of new batches of GBC-R1 started in early October at a trusted GMP site and sufficient DS is now available to supply the upcoming bioequivalence, dose response and pharmacokinetics studies. Completion of the lead validation phase is foreseen in summer 2019. In addition, GBC-HpVac is funding a post-doctoral research position on the mechanism of action of GBC-R1 at the UZH Molecular Cancer Research laboratories under Prof. Dr. Anne Müller.
GBC-HpVac is currently reaching out to further investors to support the lead optimization and preclinical phases over the following 24 months. For more information, see also gbc-hpvac.com